LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Search

Glaukos Corp

Closed

SectorHealthcare

141.62 -1.43

Overview

Share price change

24h

Current

Min

141.18

Max

147.66

Key metrics

By Trading Economics

Income

114M

-20M

Sales

7.5M

151M

EPS

-0.18

Profit margin

-13.139

Employees

1,094

EBITDA

123M

-7M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

-0.22% downside

Dividends

By Dow Jones

Next Earnings

29 Jul 2026

Market Stats

By TradingEconomics

Market Cap

806M

8B

Previous open

143.05

Previous close

141.62

News Sentiment

By Acuity

40%

60%

100 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Glaukos Corp Chart

Past performance is not a reliable indicator of future results.

Related News

28 Jan 2026, 18:25 UTC

Major Market Movers

Glaukos Shares Rise After FDA Approves NDA Supplement for iDose TR

Peer Comparison

Price change

Glaukos Corp Forecast

Price Target

By TipRanks

-0.22% downside

12 Months Forecast

Average 143.7 USD  -0.22%

High 170 USD

Low 72 USD

Based on 11 Wall Street analysts offering 12 month price targets forGlaukos Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

10

Buy

0

Hold

1

Sell

Technical Score

By Trading Central

87.61 / 93Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

100 / 345 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat